---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-23-005102"
form_type: "8-K"
ticker: "CRVS"
cik: "0001626971"
company_name: "Corvus Pharmaceuticals, Inc."
filed_at: "2023-08-08T23:59:59+00:00"
generated_at: "2026-06-12T02:07:03.367551+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Corvus reports Q2 net loss $6.5M, soquelitinib shows 3 CR/3 PR in TCL; plans FDA meeting

## Summary
- Soquelitinib Phase 1/1b: 3 complete, 3 partial responses in 20 evaluable TCL patients.
- ALC >900/mL: 6/14 objective responses; 0/6 below 900. FDA meeting for Phase 3 in Q3.
- Cash $37.0M as of June 30, 2023; projected $28-30M year-end, funding into H2 2024.
- Q2 R&D expense $4.0M (down from $4.9M); net loss $6.5M vs $8.4M in Q2 2022.
- Ciforadenant Phase 1b/2 in RCC initial data expected year-end 2023.

## SEC filing metadata
- accession: 0001171843-23-005102
- form_type: 8-K
- ticker: CRVS
- cik: 0001626971
- company_name: Corvus Pharmaceuticals, Inc.
- filed_at: 2023-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1626971/000117184323005102/0001171843-23-005102-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1626971/000117184323005102/f8k_080823.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-23-005102
- JSON: https://secwatch.observer/filing/0001171843-23-005102.json
- Plain text: https://secwatch.observer/filing/0001171843-23-005102.txt

## Key facts
- Earnings Releases
  Corvus Pharmaceuticals, Inc. reported financial results for the second quarter ended June 30, 2023.
  - Period: the second quarter ended June 30, 2023
  - Result: reported results
  source text: Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the second quarter ended June 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1626971/000117184323005102/0001171843-23-005102-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.